|
[1]www.who.int/immunization/topics/hepatitis_c/en/.
|
|
[2]Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology, 2005, 42 (4) ∶962-973.
|
|
[3]WHO. Epidemiol Rec. 2000, 75∶18-19.
|
|
[4]National Institutes of Health.National Institutes of Health Consen-sus Development Conference Statement:Management of hepatitis C[J].Hepatology, 2002, 36 (5 Suppl 1) ∶S3-20.
|
|
[5]Alberti A, Benvegnu L. Management of hepatitis C[J]. J Hepatol, 2003, 38 (Suppl 1) ∶S104-118.
|
|
[6]Kao JH, Chen DS. Transmission of hepatitis C virus in Asia: past and present perspectives[J]. J Gastroenterol Hepatol, 2000, 15 (Suppl) ∶E91-96.
|
|
[7]Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis[J]. Hepatology, 1998, 27 (5) ∶1435-1440.
|
|
[8]Niederau C, Lange S, Heintges T, et al.Prognosis of chronic hepa-titis C:results of a large, prospective cohort study[J].Hepatology, 1998, 28 (6) ∶1687-1695.
|
|
[9]Ghany MG, Strader DB, Thomas DL, et al.Diagnosis, manage-ment, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) ∶1335-1374.
|
|
[10]Neumann AU, Lam NP, Dahari H, et al.Hepatitis C viral dynam-ics in vivo and the antiviral efficacy of interferon-alphatherapy[J].Science, 1998, 282 (5386) ∶103-107.
|
|
[11]Zeuzem S, Herrmann E, Lee JH, et al.Viral kinetics in patientswith chronic hepatitis C treated with standard or peginterferon al-pha2a[J].Gastroenterology, 2001, 120 (6) ∶1438-1447.
|
|
[12]Lai MY, Kao JH, Yang PM, et al.Long-term efficacy of ribavirinplus interferon alfa in the treatment of chronic hepatitis C[J].Gas-troenterology, 1996, 111 (5) ∶1307-1312.
|
|
[13]Chuang WL, Yu ML, Dai CY, et al. Treatment of chronic hepatitis C in southern Taiwan[J]. Intervirology, 2006, 49 (1-2) ∶99-106.
|
|
[14]Hadziyannis SJ, Sette H, Morgan TR, et al.Peginterferon-al-pha2a and ribavirin combination therapy in chronic hepatitis C:arandomized study of treatment duration and ribavirin dose[J].AnnIntern Med, 2004, 140 (5) ∶346-355.
|
|
[15]Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J]. N Engl J Med, 2002, 347 (13) ∶975-982.
|
|
[16]Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial[J]. Lancet, 2001, 358 (9286) ∶958-965.
|
|
[17]Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan[J]. J Viral Hepat, 2005, 12 (3) ∶283-291.
|
|
[18]Yu ML, Dai CY, Huang JF, et al.Rapid virological response andtreatment duration for chronic hepatitis C genotype 1 patients:a ran-domized trial[J].Hepatology, 2008, 47 (6) ∶1884-1893.
|
|
[19]Liu CH, Liu CJ, Lin CL, et al. Pegylated Interferon-alpha-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial[J]. Clin Infect Dis, 2008, 47 (10) ∶1260-1269.
|
|
[20]Shiratori Y, Kato N, Yokosuka O, Predictors of the efficacy of in-terferon therapy in chronic hepatitis C virus infection.Tokyo-Chi-ba Hepatitis Research Group[J].Gastroenterology, 1997, 113 (2) ∶558-566.
|
|
[21]Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa[J]. Hepatology, 1998, 27 (4) ∶1149-1156.
|
|
[22]Chayama K, Tsubota A, Kobayashi M, et al.Pretreatment virusload and multiple amino acid substitutions in the interferon sensitivi-ty-determining region predict the outcome of interferon treatment inpatients with chronic genotype 1b hepatitis C virus infection[J].Hepatology, 1997, 25 (3) ∶745-749.
|
|
[23]Berg T, Sarrazin C, Herrmann E, et al.Prediction of treatmentoutcome in patients with chronic hepatitis C:significance of base-line parameters and viral dynamics during therapy[J].Hepatology, 2003, 37 (3) ∶600-609.
|
|
[24]Missiha S, Heathcote J, Arenovich T, et al. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C[J]. Am J Gastroenterol, 2007, 102 (10) ∶2181-2188.
|
|
[25]Bressler BL, Guindi M, Tomlinson G, et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C[J]. Hepatology, 2003, 38 (3) ∶639-644.
|
|
[26]Akuta N, Suzuki F, Suzuki Y, et al.Hepatocyte steatosis is an im-portant predictor of response to interferon (IFN) monotherapy inJapanese patients infected with HCV genotype 2a:Virological fea-tures of IFN-resistant cases with hepatocyte steatosis[J].J MedVirol, 2005, 75 (4) ∶550-558.
|
|
[27]Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C[J]. Hepatology, 2004, 39 (4) ∶1147-1171.
|
|
[28]Lin R, Liddle C, Byth K, et al.Virus and host factors are both im-portant determinants of response to interferon treatment among pa-tients with chronic hepatitis C[J].J Viral Hepat, 1996, 3 (2) ∶85-96.
|
|
[29]Hsu CS, Liu CH, Liu CJ, et al.Factors affecting early viral load de-cline of Asian chronic hepatitis C patients receivingpegylated interferonplus ribavirin therapy[J].Antivir Ther, 2009, 14 (1) ∶45-54.
|
|
[30]Fried MW, Hadziyannis SJ, Shiffman M. Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection[J]. J Hepatol, 2008, 48 (Suppl 2) ∶5A.
|
|
[31]Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study[J]. Hepatology, 2004, 40 (6) ∶1260-1265.
|
|
[32]Shiffman ML, Suter F, Bacon BR, et al.Peginterferon alfa-2aand ribavirin for16 or24 weeks in HCVgenotype 2 or3[J].NEn-gl J Med, 2007, 357 (2) ∶124-134.
|
|
[33]Yu ML, Dai CY, Huang JF, et al.Arandomised study of peginter-feron and ribavirin for 16 versus 24 weeks in patients with genotype2 chronic hepatitis C[J].Gut, 2007, 56 (4) ∶553-559.
|
|
[34]Powell EE, Jonsson JR, Clouston AD.Steatosis:co-factor in oth-er liver diseases[J].Hepatology, 2005, 42 (1) ∶5-13.
|
|
[35]Hsu CS, Kao JH. HCV Infection and Metabolic Syndrome[J]. J Formos Med Assoc, 2010, 109 (6) ∶403-407.
|
|
[36]Mason AL, Lau JY, Hoang N, et al.Association of diabetes melli-tus and chronic hepatitis C virus infection[J].Hepatology, 1999, 29 (2) ∶328-333.
|
|
[37]Hsu CS, Liu CJ, Liu CH, et al. Metabolic profiles in patients with chronic hepatitis C: a case-control study[J]. Hepatol Int, 2008, 2 (2) ∶250-257.
|
|
[38]Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States[J]. Ann Intern Med, 2000, 133 (8) ∶592-599.
|
|
[39]Adinolfi LE, Gambardella M, Andreana A, et al.Steatosis acceler-ates the progression of liver damage of chronic hepatitis C patientsand correlates with specific HCV genotype and visceral obesity[J].Hepatology, 2001, 33 (6) ∶1358-1364.
|
|
[40]Liu CJ, Jeng YM, Chen PJ, et al.Influence of metabolic syn-drome, viral genotype and antiviral therapy on superimposed fattyliver disease in chronic hepatitis C[J].Antivir Ther, 2005, 10 (3) ∶405-415.
|
|
[41]Liu CJ, Chen PJ, Jeng YM, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C[J]. J Hepatol, 2005, 43 (2) ∶235-242.
|
|
[42]Hsu CS, Liu CJ, Liu CH, et al.High hepatitis C viral load is asso-ciated with insulin resistance in patients with chronic hepatitisC[J].Liver Int, 2008, 28 (2) ∶271-277.
|
|
[43]Hsu CS, Liu CH, Liu CJ, et al. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection[J]. Am J Gastroenterol, 2009, 104 (3) ∶598-604.
|
|
[44]Hsu CS, Liu CH, Liu CJ, et al. Association of Metabolic Profiles with Hepatic Fibrosis in Chronic Hepatitis C Patients with Genotype 1 or 2 Infection[J]. J Gastroenterol Hepatol, (In press) .
|
|
[45]Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J]. Nature, 2009, 461 (7265) ∶798-801.
|
|
[46]Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J]. Nat Genet, 2009, 41 (10) ∶1100-1104.
|
|
[47]Tanaka Y, Nishida N, Sugiyama M, et al.Genome-wide associa-tion of IL28B with response to pegylated interferon-alpha and riba-virin therapy for chronic hepatitis C[J].Nat Genet, 2009, 41 (10) ∶1105-1109.
|
|
[48]Ge D, Fellay J, Thompson AJ, et al.Genetic variation in IL28Bpredicts hepatitis C treatment-induced viral clearance[J].Na-ture, 2009, 461 (7262) ∶399-401.
|
|
[49]Li M, Liu X, Zhou Y, et al.Interferon-lambdas:the modulatorsof antivirus, antitumor, and immune responses[J].J Leukoc Biol, 2009, 86 (1) ∶23-32.
|
PDF下载 ( 305 KB)
本文二维码
下载:
